Navigation Links
Quest Diagnostics Sponsors American Cancer Society's Choose You® Movement
Date:5/9/2011

MADISON, N.J., May 9, 2011 /PRNewswire/ -- Quest Diagnostics, the world's leading provider of diagnostic testing, information and services (NYSE: DGX), today announced its national sponsorship of Choose You®, the American Cancer Society's movement that inspires women to stay well by putting their health first and making healthy lifestyle choices to help prevent cancer. According to the American Cancer Society, 1 in 3 American women will get cancer in her lifetime, but there are steps women can take today to help change that statistic. More than half of cancer deaths could be prevented with healthy lifestyle choices, like maintaining a healthy weight through diet and regular exercise, avoiding tobacco products and getting regular cancer screening tests.

"We look forward to working with Quest Diagnostics as a national sponsor of the Choose You 'get regular health checks' commitment," said Terry Music, chief mission delivery officer for the American Cancer Society. "Their support will go a long way in helping women put their health first."

As part of the movement, women are encouraged to sign a Choose You Commitment, an online pledge to reach a specific, individual health goal. At ChooseYou.com, women can choose from five different health categories: eat right; get active; get regular health checks; protect your skin; and quit smoking. Quest Diagnostics is the national sponsor of the Choose You effort to remind women to 'get regular health checks.'

"Quest Diagnostics is proud to be a national sponsor of this important public health initiative," said Laure Park, Vice President, Corporate Communications and Investor Relations and the company's Corporate Citizenship Officer. "We hope that many will join us in supporting the Choose You movement, in recognizing women everywhere who care for their families, and in reminding them to also care for themselves."

Jon R. Cohen, M.D., Quest Diagnostics Senior Vice President and Chief Medical Officer said, "Our work at Quest Diagnostics is to put patients first every day. In doing so, we witness firsthand how prevention and early detection can change a life. By inspiring women to see their doctors and get their regular health checks, the American Cancer Society and its Choose You movement have the power to make a difference in American health – and for American families."

Quest Diagnostics is the world's leader in cancer diagnostics and is nationally recognized for its commitment to the health and wellness of its employees. In 2010, the company earned Cancer Gold Standard accreditation from the CEO Roundtable on Cancer in recognition of its commitment to its employees through the cancer continuum, from prevention and early detection to diagnosis, treatment and care. Quest Diagnostics Chairman, CEO and President Surya N. Mohapatra is an inaugural member of the American Cancer Society's CEOs Against Cancer® New Jersey Chapter, and the company is a 2010 Platinum Employer for Healthy Lifestyles award recipient from the National Business Group on Health for its HealthyQuest employee wellness program.

To learn more, visit QuestDiagnostics.com/ChooseYou.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: www.questdiagnostics.com.

Contacts: Barb Short, Media, 973-520-2800; Kathleen Valentine, Investors, 973-520-2900


'/>"/>
SOURCE Quest Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):